January 1, 1999Thrombosis and HaemostasisOpen Access

Low Molecular Weight Heparin versus Acenocoumarol in the Secondary Prophylaxis of Deep Vein Thrombosis

View Full Paper

Ask AI

Bookmark

Why the study?

Does nadroparin prevent recurrent venous thromboembolism compared to acenocoumarol in patients with symptomatic proximal deep vein thrombosis?

Population

202 patients with symptomatic proximal deep vein thrombosis (DVT) confirmed by phlebography.

Comparison

Nadroparin 85 anti-Xa IU/kg subcutaneous once… vs Acenocoumarol oral adjusted to maintain INR…

Design

RCT, randomly allocated (through a system of sealed envelopes)

Follow-up

one year

Authors

HBH. Bielska-FaldaMedical University of Warsaw WNW NoszczykMedical University of Warsaw MBM BielawiecMedical University of Białystok

Discussion

Member takes

Implication

Recurrence rates are comparable between nadroparin and acenocoumarol; supports LMWH as an effective alternative for DVT secondary prophylaxis.

Structured PICO

Does nadroparin prevent recurrent venous thromboembolism compared to acenocoumarol in patients with symptomatic proximal deep vein thrombosis?

Population

202 patients with symptomatic proximal deep vein thrombosis (DVT) confirmed by phlebography.

Intervention

Nadroparin 85 anti-Xa IU/kg subcutaneous once daily for at least 3 months (secondary prophylaxis), following initial therapy of nadroparin 85 anti-Xa IU/kg twice daily for 10 days.

Comparator

Acenocoumarol oral adjusted to maintain INR 2.0-3.0 for at least 3 months, following initial therapy of nadroparin 85 anti-Xa IU/kg twice daily for 10 days.

Outcome

Symptomatic recurrent venous thromboembolism within one year after the initial therapy confirmed by objective testing, and bleeding during the 3-month secondary prophylaxis.hard clinical

Nadroparin administered once daily at a weight-adjusted dose provides an effective and safe alternative to oral anticoagulants for the secondary prophylaxis of deep vein thrombosis.

Limitations

Treatment groups were not balanced with respect to the continuation of secondary prophylaxis beyond the planned 3-month period.
The sample size was relatively small.

Cite This Study

Bielska-Falda et al. (1999) studied this question.

synapsesocial.com/papers/6a7f6ab4ea270e40cde90562 https://doi.org/10.1055/s-0037-1614412

Topics

Anticoagulation in AF

View Full Paper

Ask AI

Bookmark

Implication

Recurrence rates are comparable between nadroparin and acenocoumarol; supports LMWH as an effective alternative for DVT secondary prophylaxis.

Low Molecular Weight Heparin versus Acenocoumarol in the Secondary Prophylaxis of Deep Vein Thrombosis

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Topics

Low Molecular Weight Heparin versus Acenocoumarol in the Secondary Prophylaxis of Deep Vein Thrombosis

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Also Consider

Topics

Also Consider